Circulating and Tissue Endothelin Immunoreactivit in Hypercholesterolemic Pigs

BackgroundHypercholesterolemia is characterized by a coronary vasoconstrictive response to the endothelium-dependent vasodilator acetylcholine. This abnormality may be due to reduced synthesis of endothelium-derived relaxing factor and/or enhanced synthesis and release of an endothelium-derived contracting factor. Endothelin is an endothelium-derived vasoconstrictor and mitogenic peptide that is present in normal plasma, and its circulating concentrations are elevated in disease states that are characterized by abnormal endothelium-dependent relaxation to acetylcholine. The current studies were designed to test the hypotheses that experimental hypercholesterolemia results in elevation of plasma and tissue endothelin immunoreactivity and that the abnormal acetylcholine-evoked coronary vasoconstriction in the hypercholesterolemic animals is associated with further elevation of plasma endothelin. Methods and ResultsPlasma concentrations and molecular forms of endothelin immunoreactivity were determined following 2% cholesterol diet for 4 months in pigs and during intracoronary acetylcholine administration. Second, we assessed the presence of endothelin in the coronary vascular wall by using immunohistochemistry. Hypercholesterolemia elevated plasma endothelin concentration and enhanced coronary artery tissue endothelin immunoreactivity. The endothelium-dependent vasodilator acetylcholine further increases plasma endothelin in hypercholesterolemia in association with coronary vasoconstriction. The predominant molecular form of endothelin in hypercholesterolemia is the biological active endothelin-l. ConclusionThis study suggests a role for endothelin as an early participant and a marker for the endothelial dysfunction in hypercholesterolemia as well as a participant in the atherogenic process.

[1]  E. Weber,et al.  Internalization of endothelin by cultured human vascular smooth muscle cells: characterization and physiological significance. , 1990, Molecular pharmacology.

[2]  T. Lüscher,et al.  Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. , 1992, Circulation research.

[3]  K. Margulies,et al.  Endothelin: a new cardiovascular regulatory peptide. , 1990, Mayo Clinic proceedings.

[4]  H. Shimokawa,et al.  Impaired Endothelium‐Dependent Relaxation to Aggregating Platelets and Related Vasoactive: Substances in Porcine Coronary Arteries in Hypercholesterolemia and Atherosclerosis , 1989, Circulation research.

[5]  Y. Hirata,et al.  Endothelin is a potent mitogen for rat vascular smooth muscle cells. , 1989, Atherosclerosis.

[6]  S. Diamond,et al.  Fluid flow decreases preproendothelin mRNA levels and suppresses endothelin-1 peptide release in cultured human endothelial cells. , 1991, Journal of vascular surgery.

[7]  V. Fuster,et al.  Role of high density lipoproteins in the regression of atherosclerosis. , 1992, Circulation.

[8]  N. Maulik,et al.  Release of endothelin during reperfusion of ischemic myocardium. ET-1 release from reperfused heart. , 1992, The American journal of cardiovascular pathology.

[9]  L. V. von Segesser,et al.  Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm? , 1990, Circulation.

[10]  G. Rubanyi.  Reversal of hypercholesterolemia-induced endothelial dysfunction by L-arginine. , 1991, Circulation.

[11]  D. Stewart,et al.  Increased plasma endothelin-1 in the early hours of acute myocardial infarction. , 1991, Journal of the American College of Cardiology.

[12]  H. Drexler,et al.  Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. , 1991, Circulation.

[13]  D. Faller,et al.  Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. , 1991, The Journal of clinical investigation.

[14]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (1). , 1992, The New England journal of medicine.

[15]  A. Lerman,et al.  Inhibition of Endothelium‐Derived Relaxing Factor Enhances Endothelin‐Mediated Vasoconstriction , 1992, Circulation.

[16]  G. Bilder,et al.  Modulation of vascular reactivity by vasoactive peptides in aortic rings from hypercholesterolemic rabbits. , 1992, European journal of pharmacology.

[17]  J. Cooke,et al.  Arginine Restores Cholinergic Relaxation of Hypercholesterolemic Rabbit Thoracic Aorta , 1991, Circulation.

[18]  A. Lerman,et al.  Intact and altered endothelium in regulation of vasomotion. , 1992, Circulation.

[19]  M. Kohzuki,et al.  Endothelin-1 augments pressor response to angiotensin II infusion in rats. , 1992, Hypertension.

[20]  T. Watanabe,et al.  Contribution of endogenous endothelin to the extension of myocardial infarct size in rats. , 1991, Circulation research.

[21]  K. Zitnay,et al.  Loss of Selective Endothelial Cell Vasoactive Functions Caused by Hypercholesterolemia in Pig Coronary Arteries , 1988, Circulation research.

[22]  D. Harrison,et al.  Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. , 1990, The Journal of clinical investigation.

[23]  A. Yeung,et al.  Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. , 1990, Circulation.

[24]  A. Lerman,et al.  Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. , 1991, The New England journal of medicine.

[25]  A. M. Lefer,et al.  Cardiovascular effects of acute hypercholesterolemia in rabbits. Reversal with lovastatin treatment. , 1989, The Journal of clinical investigation.

[26]  K. Margulies,et al.  Increased endothelin in experimental heart failure. , 1990, Circulation.

[27]  E. Weber,et al.  Inducible endothelin mRNA expression and peptide secretion in cultured human vascular smooth muscle cells. , 1990, Biochemical and biophysical research communications.